

Design, Sustainable Synthesis, and Programmed Reactions of Templated N-Heteroaryl Fused Vinyl Sultams

Joydev K. Laha, Shubhra Sharma, Seema Kirar, and Uttam Chand Banerjee

J. Org. Chem., **Just Accepted Manuscript** • DOI: 10.1021/acs.joc.7b01340 • Publication Date (Web): 21 Aug 2017

Downloaded from <http://pubs.acs.org> on August 22, 2017

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Design, Sustainable Synthesis, and Programmed Reactions of Templated N-Heteroaryl Fused Vinyl Sultams

Joydev K. Laha,^{*#} Shubhra Sharma,[#] Seema Kirar,[±] and Uttam C. Banerjee[±]

[#]*Department of Pharmaceutical Technology (Process Chemistry)*

National Institute of Pharmaceutical Education and Research

S. A. S. Nagar, Punjab 160062, India


E-mail: jlaha@niper.ac.in

[±]*Department of Pharmaceutical Technology (Biotechnology)*

National Institute of Pharmaceutical Education and Research

S. A. S. Nagar, Punjab 160062, India

ABSTRACT

Templated *N*-Heteroaryl Fused Vinyl Sultams in Action

A de novo design and synthesis of *N*-heteroaryl fused vinyl sultams as templates for programming chemical reactions on vinyl sultam periphery or (hetero)aryl ring is described. The key features include rational designing and sustainable synthesis of the template, customized reactions of vinyl sultams at C=C bond or involving N-S bond cleavage, and reactions on the periphery of the heteroaryl ring for late-stage diversification. The simple, easy access to the template coupled with opportunities for the synthesis of diversely functionalized heterocycles from a single template constitutes a rare study in contemporary organic synthesis.


INTRODUCTION

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Template designing for programming chemical synthesis has received increasing attention over the last two decades.¹ Rational design of templates, their convenient access in fewest possible steps, and employing them in sustainable chemical synthesis have brought the evolution of sophisticated architectures of synthetic molecules closer to realization. Templates of various origin including small organic molecules² or bio-macromolecules³ have been developed to perform a defined chemical task with remarkable fidelity. However, use of a template in diverse chemical synthesis has been limited.^{3d}

Vinyl sulfonamides are privileged chemotypes employed in peptidomimetics,⁴ anti-inflammatory drugs and other medicinal agents,⁵ and biomaterials.⁶ Despite poor reactivity of C=C bond in vinyl sulfonamides as compared to that in vinyl sulfones or sulfonates,⁷ vinyl sulfonamides have a remarkable biomedical significance owing to their innate ability to act as irreversible inhibitors of cysteine proteases through conjugate addition of the thiol group of the active site of cysteine residue.⁸ While sulfonamide functionality has been demonstrated as carbonyl bioisostere making key interactions with receptor proteins,⁹ it imparts, unlike carbonyl group, improved aqueous solubility.¹⁰ Despite the presence of two key functional groups, chemical reactivity as Michael acceptors although demonstrated less proficiently,^{8,11} and abilities to perform as agents for probing biological systems,¹² strategic design and development of vinyl sulfonamides has been the study of limited investigations.¹³

Scheme 1. Rational Design, Synthesis and Reactions of Templated *N*-Heteroaryl Fused Vinyl Sultams




Therefore, a de novo design of vinyl sulfonamides, especially cyclic vinyl sulfonamides (vinyl sultams), their expedient access, and subsequent use in diversity organic synthesis could be an aspiring object. The structural feature of a vinyl sultam **I** could include an endo-cyclic double bond adopting a syn-geometry as platform for conjugate Michael addition, pharmacophoric linchpin sulfonamide functionality, and chemoselective cleavage of N-S bond via hydrolytic or nucleophilic cleavage (Scheme 1). These aspects could secure extensive functionalizations, opportunities for the preparation of acyclic vinyl sulfonyl compounds, and preparation of transposed acyclic vinyl sulfonamides by nucleophilic cleavage of N-S bond with amines. Moreover, vinyl sultam **I** when fused to a heterocycle could display additional feature including reactions on the periphery of the heterocycle and late-stage functionalization on the substituted

1
2
3
4
5
6 arenes. Our previous experiences on palladium-catalyzed domino or convergent synthesis of
7
8 five-,¹⁴ six-,¹⁵ or seven-membered aryl-(hetero)aryl fused sultams¹⁶ and nucleophilic ring-
9
10 opening reactions of a highly reactive indole-aryl fused sultam¹⁴ provided a strong impetus to
11
12 strategic designing of templated sultams that are while elusive could execute programmed
13
14 chemical synthesis. Herein, we describe rational designing of an unprecedented template *N*-
15
16 heteroaryl fused vinyl sultam **II**, its sustainable synthesis, and multi-faceted reactivity affording
17
18 diverse functionalized *N*-heterocycles. The programmed reactions of vinyl sultams at C=C bond,
19
20 sultam ring-opening reactions via N-S bond cleavage, and reactions on the periphery of the
21
22 (hetero)aryl ring for further functionalization are the key demonstrations presented herein.
23
24
25
26
27

28 RESULTS AND DISCUSSION

29
30
31 Based on our design, *N*-heterocycles bearing an aldehyde group at the 2-position and
32
33 arylmethanesulfonyl chloride deemed viable substrates for tandem *N*-sulfonylation followed by
34
35 intramolecular Knoevenagel condensation to form structurally distinct *N*-heterocycle fused vinyl
36
37 sultams. Our study began with the reaction of model substrates, pyrrole-2-carboxaldehyde (**1a**)
38
39 and phenylmethanesulfonyl chloride (**2a**), in the presence of a base forming pyrrole-fused vinyl
40
41 sultam **3a** (Table 1). Reaction of **1a** and **2a** in the presence of 3 equiv of bases including NaNH₂,
42
43 MHMDS (M = Li or K), and organic bases¹⁷ did not produce any product (entries 1-3). However,
44
45 the screening of other inorganic bases produced dissimilar results (entries 4-5). Interestingly,
46
47 NaOEt proved effective for N-S bond cleavages in sultams.
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Optimization Studies^a

Entry	Base	Solvent	°C	% 3a ^b
1	NaNH ₂	THF	75	N.R
2 ^c	MHMDS	THF	75	N.R
3 ^d	org. base	THF	75	N.R
4 ^e	MOBu- <i>t</i>	THF	75	25-28
5 ^e	NaOEt	EtOH	75	11
6 ^f	NaH	THF	70	66
7 ^g	NaH	THF	70	72
8 ^h	NaH	THF	70	59
9 ^g	NaH	DMF	110	N.R
10 ^g	NaH	1,4-dioxane	110	Trace
11 ^g	NaH	THF	rt	Trace
12 ^g	NaH	THF	50 °C	27


^aReaction conditions: **1a** (0.5 mmol), **2a** (0.75 mmol), base (1.5 equiv), solvent (2.5 mL), temp. 12 h. ^bIsolated yields. ^cLiHMDS and KHMDS (3.0 equiv). ^dDBU and DBN (3 equiv). ^eLiOBu-*t*, KOBu-*t*, and NaOEt (3.0 equiv). ^fNaH (3.0 equiv). ^gNaH (2.5 equiv). ^hNaH (2.0 equiv).

Among various inorganic bases, NaH in THF proved effective forming **3a** in 66% yield (entry 6). While reducing the amount of NaH to 2.5 equiv had a positive impact in improving the yield, further reduction to 2.0 equiv produced inferior result (entries 7-8). The other solvents such as DMF or dioxane had detrimental effect on the yield of **3a** (entries 9-10). In the attempts to isolate the intermediate, on lowering the reaction temperature (entries 11-12), detrimental effects on the yield of the product was observed. The best result was obtained when **1a** (1 equiv) and **2a** (1.5

equiv) reacted in the presence of NaH (2.5 equiv) in THF (2.5 mL) at 70 °C for 12 h providing **3a** in 72% isolated yield. The central challenge in this investigation was to find an optimum condition that secured formation of vinyl sultam **3a**.

To expand the scope of the strategy, we utilized commercial or readily accessible pyrrole-2-carboxaldehydes and arylmethanesulfonyl chlorides that could participate in the one-pot tandem synthesis of pyrrole-fused vinyl sultams under the optimized conditions (Scheme 2).

Scheme 2. Synthesis of the Designed *N*-Heteroaryl Fused Vinyl Sultams




Pyrrole-2-carboxaldehydes containing a functional group at 5- or 4-position were viable substrates affording pyrrole-fused vinyl sultams **3b-3g** in varying yields. Similarly, di-substituted pyrrole-2-carboxaldehydes happened to be evenly competent producing sultams **3h-3k** in good yields. Notably, a di-bromo substituted vinyl sultam **3k** could augur interesting post-synthetic application. 4-substituted-phenylmethanesulfonyl chlorides (**2b-d**) also afforded the

1
2
3
4
5
6 corresponding sultam **3l-n** in moderate yields. Importantly, a bromo/chloro group could serve as
7
8 a synthetic handle for subsequent functionalization on arene ring. Other heterocycles, imidazole-
9
10 2-carboxaldehyde and indole-2-carboxaldehyde were subjected to the optimized condition
11
12 gratifyingly furnishing respective imidazole (**3o**) and indole-fused (**3q**) vinyl sultams in excellent
13
14 yields. However, imidazole-4-carboxaldehyde did not give a tandem fused vinyl sultam. Only *N*-
15
16 sulfonylated derivative of imidazole-4-carboxaldehyde **3p** was isolated in this reaction. We next
17
18 set out to extend the methodology to synthesize kindred lactam. Reaction of phenylacetyl
19
20 chloride and pyrrole-2-carboxaldehyde gave the corresponding lactam **3r** in 86% yield. Our
21
22 study indicates that use of an aliphatic methanesulfonyl chloride including (1*S*)-(+)-10-
23
24 camphorsulfonyl chloride or ethanesulfonyl chloride could exert a crucial challenge yielding *N*-
25
26 sulfonyl derivative **3t** or **3u** as the only isolable product. Only a limited success in the reaction of
27
28 **1a** and 2,2,2-trifluoroethanesulfonyl chloride under the optimized condition was realized in the
29
30 synthesis of **3v**. This experiment suggests that poor acidity of the methylene group in –
31
32 NCH₂SO₂– could explain the difficulty in intramolecular cyclization in **3t** or **3u**. The central
33
34 challenge in the preparation of *N*-heteroaryl fused vinyl sultams was to identify an optimized
35
36 condition, which yielded a sustainable synthesis of the vinyl sultams. Both the electron-
37
38 withdrawing and -donating groups screened in our study were well-tolerated to give sultams in
39
40 good to excellent yields.
41
42
43
44
45
46
47
48
49

50 Next, we investigated the reactions of vinyl sultams at C=C bond (Scheme 3). Michael addition
51
52 of thiol **4** to the vinyl sultam **3b** gave a diastomeric mixture **4a** and **4b** which are easily
53
54 separable by column chromatography, furnishing *cis*- (*J* = 9.4 Hz) and *trans*- (*J* = 6.8 Hz)
55
56 isomers respectively in a ratio (7:3) as determined by the isolated yields (eq. 1). However,
57
58 reaction of aliphatic amines, such as *n*-propylamine or morpholine and **3b** yielded only *trans*-
59
60

isomer ($J = 7.3$ Hz) of 1,4-conjugate addition product, **4c** and **4d**, respectively (eq. 2). It is noteworthy here that our template shows complete control of chemical reactivity at the vinyl bond in the presence of sulfonamide bond. Hydrogenation or LAH reduction of vinylic C=C bond in **3b** gave reduced pyrrole-fused sultam **4e** (eq. 3). 1,3-Dipolar cycloaddition reaction of azomethine ylide, generated in situ from **5**, was explored with vinyl sultams **3b-c**, which yielded novel pyrrolidine fused sultams bearing a quaternary center (**4f-g**) in good to excellent yields (eq. 4). The key discovery in this study was to uncover previously unexplored reactions of C=C double bond of vinyl sultam template. The reduced pyrrole fused sultam **4e** would have distinct reactivity to that of **3b**.


Scheme 3. Reactions Explored at the C=C Bond of Pyrrole Fused Vinyl Sultam



During the course of our current study, one of our defined objectives was to uncover previously unexplored chemoselective N-S bond cleavage (*N*-desulfonation)¹⁸ in vinyl sultams

with a suitable nucleophile. Unlike our previous study on ring-cleavage of biaryl sultam,¹⁴ the chemoselective N-S bond cleavage in vinyl sultams posed an intrinsic challenge due to the presence of vinyl sulfonamide, a Michael acceptor. Predictably, the amine nucleophiles were unsuccessful in N-S bond cleavage in pyrrole-fused sultams (*cf.* eq. 2, Scheme 3). However, treatment of sultam **3a** with excess NaOEt resulted N-S bond cleavage affording diarylvinyl sulfonate (**5a**) and (*E*)-diarylalkene (**5b**) (eq. 5, Scheme 4).

Scheme 4. Reactions explored at the N-S bond of vinyl sultam




Under a similar condition reaction of **3e** and **6** gave diarylvinyl sulfonates **5c-d** (eq. 6). Importantly, the preparation of a vinyl sulfonate from vinyl sultam could complement the literature protocol. However, reaction of **3b-c** containing an ester group at C-5 position and NaOEt furnished (*E*)-diarylalkenes **5e-f** (eq. 7). Interestingly, phenylmagnesium bromide also produced the similar results (eq 7). The formation of desulfonylated product **5e-f** in the presence of two different nucleophiles is especially noteworthy. Notably, the chemoselective N-S bond

1
2
3
4
5
6 cleavage in pyrrole-fused sultams appears to be primarily dependent upon the substituents
7 present on the pyrrole ring.
8
9

10
11 For studying the mechanism of the substituent dependent N-S bond cleavage, based on the
12 formation of products **5a** and **5b**, we carried out a control experiment for the synthesis of diaryl
13 alkene from diarylvinyl sulfonate in the presence of NaOEt. However, only a trace amount of **5b**
14 was observed in 2 h suggesting slow desulfonylation. Based on our previous experiences on
15 nucleophilic ring opening of sultams via N-S bond cleavage, it may be stated that alkoxide reacts
16 with the pyrrole sultam to give vinyl sulfonate via ring opening of the sultam. The vinyl
17 sulfonate could undergo desulfonylation to yield the corresponding alkene.^{18a} A plausible
18 mechanism could be the NaOEt mediated N-S bond cleavage followed by subsequent
19 desulfonylation from the anionic intermediate prior to proton abstraction. In the presence of an
20 electron-withdrawing group, the negative charge on pyrrole nitrogen is stabilized facilitating fast
21 desulfonylation resulting in diaryl alkenes, whereas in case of other substituents diarylvinyl
22 sulfonates are obtained.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

40 In contrast to these results, reaction of pyrrole-fused vinyl sultams **3a-b,e** and NaH at an elevated
41 temperature (70 °C) produced synthetically useful diarylalkynes **5g-i**, demonstrating the simple,
42 yet rapid efficient synthesis of C2-alkynyl(NH)pyrroles (eq. 8). The formation of alkynes from
43 pyrrole sultam could follow a different pathway. In this case, a β -elimination could occur on
44 pyrrole sultam, which upon subsequent SO₂ extrusion could form alkynes.^{18b} However,
45 mechanism for the formation of alkenes or alkynes from pyrrole sultams is a subject of further
46 investigation. The key distinctive features of the pyrrole-fused vinyl sultam template include
47 ability to be diversified affording vinyl sulfonates, diarylalkenes, and diarylalkynes under N-S
48 bond cleavage conditions.
49
50
51
52
53
54
55
56
57
58
59
60

We also explored the chemical reactivity of the pyrrole-fused sultam **3a** towards aromatic electrophilic substitution. Mono-bromination of pyrrole-fused sultam **6** using NBS occurred exclusively at the C-5 position providing a synthetic handle for late-stage diversification (eq. 9).



In conclusion, we have demonstrated, for the first time, that *N*-heterocycle fused vinyl sultams could be a useful template for programming chemical synthesis. The sustainable synthesis of the templates from *N*-heterocycles bearing an aldehyde group and arylmethanesulfonyl chlorides employing only sodium hydride as the reagent is especially noteworthy. The template presents a formidable framework that enables a variety of previously unexplored paradigm of reactions. The operational simplicity to prepare the templates and explicit use of classical reactions on the designed templates are the central features of this study. Future strides in this area could unveil many formidable templates that could reveal boundless importance of these templates in diversity organic synthesis.

EXPERIMENTAL SECTION

General Methods: Unless noted otherwise, all reagents and solvents were purchased from commercial sources and used as received. All palladium-catalyzed reactions were performed in a screw-cap sealed tube. The ^1H and ^{13}C NMR spectra were obtained in CDCl_3 as solvent using a 400 MHz spectrometer with Me_4Si as an internal standard. Coupling constants (J values) are reported in Hz. Column chromatography was performed using silica gel (100-200 mesh). High

1
2
3
4
5
6 resolution mass spectra (HRMS) were obtained using electron spray ionisation (ESI) technique
7
8 and as TOF mass analyser. All melting points were taken using a melting point apparatus
9
10 equipped with a calibrated thermometer and are uncorrected. New compounds were
11
12 characterized by melting point, IR, ¹H NMR, ¹³C NMR, and HRMS data.
13
14

16 **1. Typical Procedure for Substituted Pyrrole synthesis (1aa-1ae)**¹⁹

17
18 Following a literature procedure, to a solution of sodium hydride (2 equiv) in THF (10 mL),
19
20 solution of *p*-toluenesulfonylmethylisocyanide (10 mmol) and michael acceptor (10 mmol) in
21
22 THF (10 mL) was added dropwise. As reaction mixture turned brownish upon addition, reaction
23
24 was allowed to continue overnight. Following which water (10 mL) was added and it was
25
26 extracted with EtOAc (3 x 10 mL). The combined organic layer was concentrated under reduced
27
28 pressure and washed with hexane to give substituted pyrrole.
29
30
31
32

33 **2. General Procedure for Formylation of Pyrroles (1b-c, 1e-f, 1h-j)**²⁰

34
35 The Vilsmeier reagent was prepared by adding POCl₃ (5.0 mmol) dropwise to ice cold dry DMF
36
37 (5 mL) under stirring. The mixture was then stirred for 10-15 min at 0 °C. To the above
38
39 Vilsmeier reagent was added substituted pyrrole (1.0 mmol) as a solution in DCE (5.0 mL). Then
40
41 the mixture was allowed to warm to 100 °C and was stirred for 1.0 h. After the starting material
42
43 was consumed (monitored by TLC), the reaction mixture was poured into saturated sodium
44
45 chloride aqueous (50 mL). The mixture was extracted with dichloromethane (3 × 20 mL), the
46
47 combined organic phase was washed with water (3 × 20 mL), dried over MgSO₄, filtered and
48
49 concentrated in vacuo. The crude product was purified by flash chromatography (silica gel, Ethyl
50
51 acetate: Hexanes = 2:8 to 1:1) to give desired product.
52
53
54
55
56

57 **3. Standard Procedure for Nitration of Pyrrole (1d)**²¹

1
2
3
4
5
6 In an oven-dried screw cap vial equipped with a magnetic stir bar, the solution of Pyrrole-2-
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

In an oven-dried screw cap vial equipped with a magnetic stir bar, the solution of Pyrrole-2-carboxaldehyde (0.5 mmol) in carbon tetrachloride (2.5 mL) was treated with copper nitrate trihydrate (1.5 equiv) and acetic anhydride (5 equiv) and heated at 50 °C. After completion of the reaction (monitored by TLC), the reaction mixture was quenched with H₂O (10 mL) and extracted with EtOAc (20 mL X 2). The organic layer was dried (Na₂SO₄) and concentrated, which upon chromatography [silica, EtOAc: Hexanes = 1:9] gave the desired product.

4. Standard Procedure for Bromination of Pyrroles (1g, 1k, 6)²²

To the solution of substrate (0.5 mmol) in DMF (4.0 mL) at 0 °C was added recrystallized *N*-Bromosuccinimide (1.1 equiv) which gave rusty solution. After completion of the reaction (monitored by TLC), the mixture turned light yellow and was quenched with saturated solution of sodium sulfite (10 mL) and extracted with EtOAc (10 mL X 2). The organic layer was dried (Na₂SO₄) and concentrated, which upon chromatography [silica, EtOAc: Hexanes = 0.5:9.5] gave the corresponding brominated product.

5. General procedure for the synthesis of arylmethanesulfonyl chloride (2b-d)²³

4-substituted benzyl bromide (5.0 mmol) were added dropwise to a solution of sodium sulfite (5.0 mmol) in aqueous NaOH (10%, 5 mL) and the reaction mixture was heated at reflux for 4 h. After cooling the solution in an ice bath, the corresponding sodium arylmethanesulfonates were purified by recrystallization from CH₃OH (95%). The intermediate (2.5mmol) was then treated with thionyl chloride (10.0mmol) in DMF (2.5 mL) for 3 h at room temperature. The residue was subsequently poured into the ice-water mixture and the solid was then extracted with diethyl ether (3-20 mL). After removing the solvent under reduced pressure, desired product was obtained.

6. Synthesis of *N*-Heteroaryl-fused Vinyl Sultams (3a-v)

In an oven-dried screw cap vial equipped with a magnetic stir bar, sodium hydride (2.5 equiv) was added portion wise to an ice cold solution of formylated pyrrole substrate (0.5mmol) in freshly distilled anhydrous THF (2.5 mL). To this reaction mixture was added phenyl methane sulfonyl chloride (1.5 equiv) portion wise and was heated at 70 °C for 12 h. The reaction mixture was allowed to cool to room temperature and neutralized by the addition of saturated solution of NaCl (10 mL). Then, it was extracted with ethyl acetate (2 x 10 mL). The combined organic layer was dried (Na₂SO₄), concentrated under reduced pressure, and purified by column chromatography on silica using (EtOAc: Hexanes = 1:9 to 3:7) as an eluent to give the desired product.

7. General Procedure for Michael Addition at Vinyl Sulfonamide using Thiols and Amines (4a-d)

In an oven-dried screw cap vial equipped with a magnetic stir bar, substrate (0.2 mmol) was treated with methyl 3-mercaptopropanoate (0.26 mmol) in the presence of triethylamine (1.2 equiv) in methanol (1 mL) at room temperature for 15min. The solvent was removed under reduced pressure and the reaction mixture was then diluted with H₂O (5 mL) and extracted with EtOAc (10 mL X 2). The organic layer was dried (Na₂SO₄) and concentrated, which upon chromatography [silica, EtOAc: Hexanes = 3:7] gave the corresponding michael addition product.

In an oven-dried screw cap vial equipped with a magnetic stir bar, substrate (0.2 mmol) was treated with amine (1 mL) at 40 °C for 1 h. After completion of the reaction (monitored by TLC), The solvent was removed under reduced pressure and the reaction mixture was diluted with H₂O (5 mL) and extracted with EtOAc (10 mL X 2). The organic layer was dried (Na₂SO₄) and

1
2
3
4
5
6 concentrated, which upon chromatography [silica, EtOAc: Hexanes = 2:8] gave the
7
8 corresponding michael addition product.
9

10 11 **8. General Procedure for Hydrogenation of Vinyl Sultams (4e)**

12
13 The vinyl sultam substrate (0.2 mmol), Pd/C (10 mol%) and methanol were added in the reaction
14
15 tube and then sealed. The reaction tube was thrice evacuated and flushed with hydrogen and
16
17 heated at 40 °C under hydrogen atmosphere. After the starting material was consumed (monitored
18
19 by TLC), the reaction mixture was diluted with methanol and passed through celite. The
20
21 combined organic layer was concentrated under reduced pressure and washed with hexane to get
22
23 reduced product.
24
25
26

27
28 In a perfectly dried two-necked flask, an ice-cold solution of substrate (0.2 mmol) and freshly
29
30 distilled THF (3.0 mL) under nitrogen was treated with LAH (4 equiv) portion wise. The
31
32 reaction was allowed to warm at room temperature and after the starting material was consumed
33
34 (monitored by TLC), the reaction was quenched with sodium hydroxide and extracted with EtOAc
35
36 (20 mL X 2). The organic layer was dried (Na₂SO₄) and concentrated, which upon flash
37
38 chromatography [silica, EtOAc: Hexanes = 2:8] gave the corresponding reduced product.
39
40
41
42

43 **9. General Procedure for Cycloaddition with Azomethine Ylide Precursor (4f-g)²⁴**

44
45 In an oven-dried aluminium foil coated screw-cap vial with a magnetic bar, vinyl sultam (0.2
46
47 mmol, 1 equiv) and Ag(I)F (2.2 equiv) were taken. [Note: Ag(I)F was completely dried under
48
49 vacuum at 55-60 °C at least for 30 min with aluminium foil coating before use]. The vial was
50
51 purged three times with nitrogen and kept under ice bath. A solution of the azomethine ylide
52
53 precursor (1.1 equiv) in anhydrous DCM (1 mL) was added dropwise . The ice-bath was
54
55 removed, and the reaction mixture was stirred at room temperature for 10-15 min under nitrogen
56
57
58
59
60

1
2
3
4
5
6 atmosphere. The reaction mixture was then diluted with 5 mL DCM and passed through a celite
7
8 bed. The filtrate was concentrated in vacuo and purified by column chromatography (100-200#
9
10 silica, ethyl acetate: hexane) to give the desired spirocyclic compound.
11
12

13
14 **10. General Procedure for Cleavage of N-S bond to form Sulfonate Ester and/orDiaryl**
15
16 **Alkene using NaOEt(5a-f)**
17

18 In an oven-dried screw cap vial equipped with a magnetic stir bar, a solution of substrate (0.2
19 mmol) in THF (2 mL) was treated with freshly prepared sodium ethoxide solution in ethanol
20 (0.25mmol) at room temperature. After the starting material was consumed (monitored by TLC),
21 the reaction mixture was quenched with H₂O (10 mL) and extracted with EtOAc (20 mL X 2).
22
23 The organic layer was dried (Na₂SO₄) and concentrated, which upon chromatography [silica,
24 EtOAc: Hexanes = 1:9] gave the corresponding sulfonate ester and/or diaryl alkene.
25
26
27
28
29
30
31
32

33 **11. General Procedure for Cleavage of N-S bond using Phenylmagnesiumbromide (5e-f)**
34

35 In an oven-dried screw cap vial equipped with a magnetic stir bar, a solution of substrate (0.2
36 mmol) in THF (1 mL) was treated with phenylmagnesiumbromide (0.5 mL, 1M solution in THF)
37 at 60 °C for 2 h. After the starting material was consumed (monitored by TLC), saturated solution
38 of ammonium chloride (2 mL) was added and the mixture was diluted with H₂O (10 mL) and
39 extracted with EtOAc (20 mL X 2). The organic layer was dried (Na₂SO₄) and concentrated,
40 which upon chromatography [silica, EtOAc: Hexanes = 1:9] gave the desulfonylated product.
41
42
43
44
45
46
47
48
49

50 **12. General Procedure for Synthesis of Diaryl Alkynes using NaH (5g-i)**
51

52 In an oven-dried screw cap vial equipped with a magnetic stir bar, a solution of substrate
53 (0.2mmol) in THF (2 mL) was treated with sodium hydride (1.2 equiv) and allowed to heat at 70
54 °C. After the starting material was consumed (monitored by TLC), the reaction mixture was
55
56
57
58
59
60

1
2
3
4
5
6 quenched with H₂O (10 mL) and extracted with EtOAc (20 mL X 2). The organic layer was
7
8 dried (Na₂SO₄) and concentrated, which upon chromatography [silica, EtOAc: Hexanes =
9
10 0.5:9.5] gave the corresponding diaryl alkynes.
11
12

13 14 COMPOUNDS CHARACTERIZATION DATA

15
16
17 **1*H*-Pyrrole-3-carbonitrile (1aa):** Colorless liquid (71 mg, 77%); IR (DCM, cm⁻¹): 3307, 2961,
18
19 2249, 1423, 1058, 729; ¹H NMR (CDCl₃): δ 9.35 (bs, 1H), 7.33-7.32 (m, 1H), 6.83 (dd, *J* = 2.3,
20
21 2.5 Hz, 1H), 6.49 (s, 1H); ¹³C NMR (CDCl₃): δ 126.0, 119.4, 117.3, 111.6; HRMS (ESI) *m/z*
22
23 calcd for C₅H₅N₂ [M+H]⁺ 93.0453, found 93.0451.
24
25

26
27 **Methyl 1*H*-pyrrole-3-carboxylate (1ab):** Colorless solid (114 mg, 89%); mp.87-89 °C; IR
28
29 (KBr, cm⁻¹): 3382, 2952, 1687, 1335, 1161, 765; ¹H NMR (CDCl₃): δ 8.52 (bs, 1H), 7.44 (s, 1H),
30
31 6.77 (d, *J* = 2.2 Hz, 1H), 6.66 (s, 1H), 3.82 (s, 3H); ¹³C NMR (CDCl₃): δ 165.4, 123.4, 118.7,
32
33 116.3, 109.8, 51.1; HRMS (ESI) *m/z* calcd for C₆H₈NO₂ [M+H]⁺ 126.0555, found 126.0550.
34
35

36
37 **Diethyl 1*H*-pyrrole-3,4-dicarboxylate (1ac):** Colorless solid (194 mg, 92%); ¹H NMR
38
39 (CDCl₃): δ 9.59 (bs, 1H), 7.37 (s, 2H), 4.33 (d, *J* = 7.1 Hz, 4H), 1.36 (m, 6H); ¹³C NMR
40
41 (CDCl₃): δ 164.0, 164.2, 125.6, 115.9, 60.2, 28.2, 14.3; HRMS (ESI) *m/z* calcd for C₁₀H₁₄NO₄
42
43 [M+H]⁺ 212.0923, found 212.0927.
44
45

46
47 **Ethyl 4-methyl-1*H*-pyrrole-3-carboxylate (1ad):** Colorless solid (126 mg, 83%); mp.61-62 °C;
48
49 IR (KBr, cm⁻¹): 3325, 2925, 1685, 1323, 1154, 778, 600; ¹H NMR (CDCl₃): δ 8.64 (bs, 1H), 7.39
50
51 (dd, *J* = 2.3, 3.0 Hz, 1H), 6.55 (dd, *J* = 0.9, 2.0 Hz, 1H), 4.31 (d, *J* = 7.2 Hz, 2H), 2.30 (d, *J* = 0.9
52
53 Hz, 3H), 1.37 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (CDCl₃): δ 165.8, 124.4, 121.0, 117.3, 114.8, 59.4,
54
55 14.5, 11.7; HRMS (ESI) *m/z* calcd for C₈H₁₂NO₂ [M+H]⁺ 154.0868, found 154.0872.
56
57
58
59
60

1
2
3
4
5
6 **Methyl 4-methyl-1H-pyrrole-3-carboxylate (1ae):** Colorless solid (128 mg, 92%); mp.125-126
7
8 °C; IR (KBr, cm⁻¹): 3326, 2920, 1688, 1325, 1154, 702; ¹H NMR (CDCl₃): δ 8.87 (bs, 1H), 7.38
9
10 (dd, *J* = 2.2, 3.1 Hz, 1H), 6.54 (dd, *J* = 1.0, 2.0 Hz, 1H), 3.81 (s, 3H), 2.30 (d, *J* = 0.9 Hz, 3H);
11
12 ¹³C NMR (CDCl₃): δ 165.6, 124.3, 121.0, 117.2, 115.0, 59.3, 11.6; HRMS (ESI) *m/z* calcd for
13
14 C₇H₁₀NO₂ [M+H]⁺ 140.0712, found 140.0711.
15
16

17
18 **Methyl 5-formyl-1H-pyrrole-2-carboxylate (1b):** Colorless solid (116 mg, 76%); mp.100-101
19
20 °C; IR (KBr, cm⁻¹): 3300, 2959, 1730, 1675, 1264, 761; ¹H NMR (CDCl₃): δ 10.04 (bs, 1H),
21
22 9.68 (s, 1H), 6.96 (dd, *J* = 1.6, 2.2 Hz, 2H), 3.93 (s, 3H); ¹³C NMR (CDCl₃): δ 180.4, 160.8,
23
24 134.4, 128.1, 119.7, 115.2, 52.2; HRMS (ESI) *m/z* calcd for C₇H₈NO₃ [M+H]⁺ 154.0504, found
25
26 154.0509.
27
28

29
30 **Ethyl 5-formyl-1H-pyrrole-2-carboxylate (1c):** Colorless solid (146 mg, 87%); mp.78-79 °C;
31
32 IR (KBr, cm⁻¹): 3134, 2958, 1730, 1269, 994, 765; ¹H NMR (CDCl₃): δ 10.28 (bs, 1H), 9.68 (s,
33
34 1H), 6.96-6.93 (m, 2H), 4.42 (q, *J* = 7.1 Hz, 2H), 1.40 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (CDCl₃): δ
35
36 180.5, 160.4, 134.4, 128.6, 119.7, 115.6, 61.4, 14.2; HRMS (ESI) *m/z* calcd for C₈H₁₀NO₃
37
38 [M+H]⁺ 168.0661, found 168.0665.
39
40
41

42
43 **4-Nitro-1H-pyrrole-2-carbaldehyde (1d):** Colorless solid (74 mg, 53%); mp.131-132 °C; IR
44
45 (KBr, cm⁻¹): 3444, 2079, 1666, 1392, 1073, 752; ¹H NMR (CDCl₃): δ 10.29 (bs, 1H), 9.61 (s,
46
47 1H), 7.90 (s, 1H), 7.48 (s, 1H); ¹³C NMR (CDCl₃): δ 186.4 (d, *J* = 7 Hz), 142.3, 137.1, 131.5,
48
49 119.5; HRMS (ESI) *m/z* calcd for C₅H₅N₂O₃ [M+H]⁺ 141.0300, found 141.0302.
50
51
52

53 **5-Formyl-1H-pyrrole-3-carbonitrile (1e):** Colorless solid (78 mg, 65%); mp.143-145 °C; IR
54
55 (KBr, cm⁻¹): 3304, 2917, 2224, 1667, 1422, 1057, 728; ¹H NMR (DMSO-D₆): δ 13.05 (bs, 1H),
56
57 9.55 (d, *J* = 0.7 Hz, 1H), 7.99 (s, 1H), 7.48 (d, *J* = 1.3 Hz, 1H); ¹³C NMR (DMSO-D₆): δ 180.7,
58
59
60

1
2
3
4
5
6 133.7, 133.5, 123.0, 116.2, 94.2; HRMS (ESI) m/z calcd for $C_6H_5N_2O$ $[M+H]^+$ 121.0402, found
7
8 121.0407.
9

10
11 **Methyl 5-formyl-1*H*-pyrrole-3-carboxylate (1f):** Colorless solid (120 mg, 79%); mp.135-136
12 °C; IR (KBr, cm^{-1}): 3255, 1664, 1398, 1185, 1001, 764; 1H NMR ($CDCl_3$): δ 10.53 (bs, 1H),
13
14 9.57 (d, $J = 0.9$ Hz, 1H), 7.74-7.73 (m, 1H), 7.42 (dd, $J = 1.4, 2.4$ Hz, 1H), 3.87 (s, 3H); ^{13}C
15
16 NMR ($CDCl_3$): δ 180.1, 164.0, 133.0, 130.0, 121.6, 118.7, 51.5; HRMS (ESI) m/z calcd for
17
18 $C_7H_8NO_3$ $[M+H]^+$ 154.0504, found 154.0506.
19
20
21
22

23
24 **4-Bromo-1*H*-pyrrole-2-carbaldehyde (1g):** Colorless solid (79 mg, 46%); mp.122-124 °C; IR
25
26 (KBr, cm^{-1}): 3252, 3108, 2923, 1667, 1357, 770; 1H NMR ($CDCl_3$): δ 9.96 (bs, 1H), 9.47 (s, 1H),
27
28 7.13 (s, 1H), 6.98 (s, 1H); ^{13}C NMR ($CDCl_3$): δ 178.9, 132.6, 126.1, 122.2, 98.8; HRMS (ESI)
29
30 m/z calcd for C_5H_5BrNO $[M+H]^+$ 173.9555, found 173.9558.
31
32
33

34
35 **Diethyl 2-formyl-1*H*-pyrrole-3,4-dicarboxylate (1h):** Colorless solid (164 mg, 69%); mp.149-
36
37 151 °C; IR (KBr, cm^{-1}): 34433, 2825, 2067, 1667, 1285, 1190, 766; 1H NMR ($CDCl_3$): δ 10.48
38
39 (bs, 1H), 9.90 (d, $J = 0.5$ Hz, 1H), 7.61-7.60 (m, 1H), 4.46 (q, $J = 7.1$ Hz, 2H), 4.35 (q, $J = 7.1$
40
41 Hz, 1H), 1.42-1.33 (m, 6H); ^{13}C NMR ($CDCl_3$): δ 180.9, 163.2, 162.7, 132.4, 128.7, 124.3,
42
43 118.3, 61.8, 60.8, 14.2, 14.1; HRMS (ESI) m/z calcd for $C_{11}H_{14}NO_5$ $[M+H]^+$ 240.0872, found
44
45 240.0871.
46
47
48

49
50 **Ethyl 5-formyl-4-methyl-1*H*-pyrrole-3-carboxylate (1i):** Colorless solid (135 mg, 75%);
51
52 mp.118-120 °C; IR (KBr, cm^{-1}): 3325, 2855, 1685, 1451, 1154, 778; 1H NMR ($CDCl_3$): δ 10.37
53
54 (bs, 1H), 9.71 (s, 1H), 7.69 (d, $J = 3.3$ Hz, 1H), 4.34 (d, $J = 7.1$ Hz, 2H), 2.62 (s, 3H), 1.38 (d, J
55
56 = 7.1 Hz, 3H); ^{13}C NMR ($CDCl_3$): δ 178.5, 164.2, 134.5, 130.7, 130.5, 117.2, 59.9, 14.4, 10.0;
57
58 HRMS (ESI) m/z calcd for $C_9H_{12}NO_3$ $[M+H]^+$ 182.0817, found 182.0814.
59
60

1
2
3
4
5
6 **Methyl 5-formyl-4-methyl-1H-pyrrole-3-carboxylate (1j):** Colorless solid (131 mg, 79%);
7
8 mp.137-138 °C; IR (KBr, cm⁻¹): 3246, 2927, 1638, 1264, 1171, 805; ¹H NMR (CDCl₃): δ 10.18
9
10 (bs, 1H), 9.72 (s, 1H), 7.67 (d, *J* = 3.4 Hz, 1H), 3.85 (s, 3H), 2.62 (s, 3H); ¹³C NMR (CDCl₃): δ
11
12 178.5, 164.5, 134.3, 130.5, 130.5, 116.9, 51.2, 9.9; HRMS (ESI) *m/z* calcd for C₈H₁₀NO₃
13
14 [M+H]⁺ 168.0661, found 168.0659.
15
16

17
18 **4,5-Dibromo-1H-pyrrole-2-carbaldehyde (1k):** Colorless solid (164 mg, 69%); mp.144-146
19
20 °C; IR (KBr, cm⁻¹): 3434, 3108, 2860, 1661, 1357, 770; ¹H NMR (CDCl₃): δ 10.56 (bs, 1H),
21
22 9.35 (s, 1H), 6.98 (s, 1H); ¹³C NMR (CDCl₃): δ 181.0, 132.4, 129.1, 124.3, 118.1; HRMS (ESI)
23
24 *m/z* calcd for C₅H₄Br₂NO [M+H]⁺ 251.8660, found 251.8663.
25
26

27
28 **(4-Bromophenyl)methanesulfonyl chloride (2b):** Colorless solid (126 mg, 83%); mp.110-112
29
30 °C; IR (KBr, cm⁻¹): 3397, 2921, 1770, 1371, 1246, 749; ¹H NMR (DMSO-D₆): δ 7.44 (dd, *J* =
31
32 1.8, 6.5 Hz, 2H), 7.25 (d, *J* = 8.6 Hz, 2H), 3.69 (s, 2H); ¹³C NMR (DMSO-D₆): δ 139.6, 137.6,
33
34 135.6, 124.8, 61.7; HRMS (ESI) *m/z* calcd for C₇H₇BrClO₂S [M+H]⁺ 268.9039, found 268.9033.
35
36
37

38 **(4-Chlorophenyl)methanesulfonyl chloride (2c):** Colorless solid (85 mg, 77%); ¹H NMR
39
40 (CDCl₃): δ 7.48-7.43 (m, 4H), 4.85 (s, 2H).
41
42
43

44 ***p*-Tolylmethanesulfonyl chloride (2d):** Colorless solid (82 mg, 81%); ¹H NMR (CDCl₃): δ 7.39
45
46 (d, *J* = 8.0 Hz, 2H), 7.29 (d, *J* = 8.0 Hz, 2H), 4.85 (s, 2H).
47
48

49 **2-Phenylpyrrolo[1,2-*b*]isothiazole 1,1-dioxide (3a):** Colorless solid (16 6 mg, 72%); mp.118-
50
51 120 °C; IR (KBr, cm⁻¹): 2924, 1588, 1323, 1170, 756, 651; ¹H NMR (CDCl₃): δ 7.72-7.69 (m,
52
53 2H), 7.51-7.44 (m, 3H), 7.26 (s, 1H), 7.22 (d, *J* = 3.0 Hz, 1H), 6.43 (t, *J* = 3.2 Hz, 1H), 6.37 (dd,
54
55 *J* = 0.7 Hz, 3.3 Hz, 1H); ¹³C NMR (CDCl₃): δ 140.2, 129.9, 129.3, 128.6, 127.1, 125.7, 118.5,
56
57 118.4, 116.9, 109.4; HRMS (ESI) *m/z* calcd for C₁₂H₁₀NO₂S [M+H]⁺232.0432, found 232.0428.
58
59
60

1
2
3
4
5
6 **Methyl 2-phenylpyrrolo[1,2-b]isothiazole-6-carboxylate 1,1-dioxide (3b):** Yellowish solid
7
8 (118 mg, 82%); mp.154-155 °C; IR (KBr, cm⁻¹): 3418, 2924, 2853, 1645, 1154, 749; ¹H NMR
9
10 (CDCl₃): δ 7.74-7.71 (m, 2H), 7.48-7.47 (m, 3H), 7.19 (s, 1H), 7.01 (d, *J* = 3.6 Hz, 1H), 6.32 (d,
11
12 *J* = 3.6 Hz, 1H), 3.96 (s, 3H); ¹³C NMR (CDCl₃): δ 159.1, 142.7, 133.0, 130.6, 129.4, 126.7,
13
14 126.4, 126.1, 122.6, 116.4, 108.6, 52.4; HRMS (ESI) *m/z* calcd for C₁₄H₁₂NO₄S [M+H]⁺
15
16 290.0487, found 290.0492.
17
18

19
20 **Ethyl 2-phenylpyrrolo[1,2-b]isothiazole-6-carboxylate 1,1-dioxide (3c):** Yellowish solid (110
21
22 mg, 73%); mp.125-127 °C; IR (KBr, cm⁻¹): 3421, 2924, 1289, 1182, 751; ¹H NMR (CDCl₃): δ
23
24 7.75-7.73 (m, 2H), 7.50-7.47 (m, 3H), 7.20 (s, 1H), 7.03 (d, *J* = 3.6 Hz, 1H), 6.33 (d, *J* = 3.6 Hz,
25
26 1H) 4.47 (q, *J* = 7.1 Hz, 2H), 1.46 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (CDCl₃): δ 158.6, 142.5, 132.9,
27
28 130.5, 129.4, 126.9, 126.7, 126.1, 122.6, 116.4, 108.6, 61.7, 14.1; HRMS (ESI) *m/z* calcd for
29
30 C₁₅H₁₄NO₄S [M+H]⁺ 304.0644, found 304.0648.
31
32
33

34
35 **5-Nitro-2-phenylpyrrolo[1,2-b]isothiazole 1,1-dioxide (3d):** Yellowish solid (117 mg, 85%);
36
37 mp.187-188 °C; IR (KBr, cm⁻¹): 3269, 2882, 1508, 1310, 1104, 749; ¹H NMR (CDCl₃): δ 8.05
38
39 (s, 1H), 7.72-7.70 (m, 2H), 7.54-7.53 (m, 3H), 7.30 (s, 1H), 6.92 (d, *J* = 1.0 Hz, 1H); ¹³C NMR
40
41 (CDCl₃): δ 141.8, 131.2, 129.7, 127.1, 126.2, 125.7, 117.9, 117.0, 103.3; HRMS (ESI) *m/z* calcd
42
43 for C₁₂H₉N₂O₄S [M+H]⁺ 277.0283, found 277.0285.
44
45
46

47
48 **2-Phenylpyrrolo[1,2-b]isothiazole-5-carbonitrile 1,1-dioxide (3e):** Off-white solid (113 mg,
49
50 89%); mp.138-140 °C; IR (KBr, cm⁻¹): 3433, 3124, 2232, 1634, 1342, 1158, 749; ¹H NMR
51
52 (CDCl₃): δ 7.71-7.68 (m, 3H), 7.53 (t, *J* = 3.2 Hz, 3H), 7.28 (s, 1H), 6.58 (d, *J* = 0.9, 1H); ¹³C
53
54 NMR (CDCl₃): δ 131.0, 129.6, 128.6, 126.1, 125.9, 124.6, 117.1, 113.7, 109.8, 101.6; HRMS
55
56 (ESI) *m/z* calcd for C₁₃H₉N₂O₂S [M+H]⁺ 257.0385, found 257.0379.
57
58
59
60

1
2
3
4
5
6 **Methyl 2-phenylpyrrolo[1,2-b]isothiazole-5-carboxylate 1,1-dioxide (3f):** Yellowish solid
7
8 (109 mg, 76%); mp.183-184 °C; IR (KBr, cm⁻¹): 3439, 2924, 2091, 1644, 1206, 750; ¹H NMR
9
10 (DMSO-D₆): δ 8.53 (s, 1H), 8.11 (s, 1H), 7.77 (d, *J* = 7.1 Hz, 2H), 7.59-7.52 (m, 3H), 6.87 (s,
11
12 1H), 3.79 (s, 3H); ¹³C NMR (CDCl₃): δ 163.3, 140.8, 130.5, 129.5, 128.4, 126.4, 125.9, 123.9,
13
14 122.4, 118.1, 108.9, 51.8; HRMS (ESI) *m/z* calcd for C₁₄H₁₂NO₄S [M+H]⁺ 290.0487, found
15
16 290.0482.
17
18

19
20
21 **5-Bromo-2-phenylpyrrolo[1,2-b]isothiazole 1,1-dioxide (3g):** Off-white solid (103mg, 67%);
22
23 mp.138-139 °C; IR (KBr, cm⁻¹): 3420, 1445, 1216, 1143, 921, 754, 569; ¹H NMR (CDCl₃): δ
24
25 7.70-7.68 (m, 2H), 7.52-7.47 (m, 3H), 7.23 (s, 2H), 6.39 (s, 1H); ¹³C NMR (CDCl₃): δ 140.6,
26
27 130.4, 129.4, 128.3, 126.5, 125.9, 117.6, 117.4, 111.5, 104.6; HRMS (ESI) *m/z* calcd for
28
29 C₁₂H₉BrNO₂S [M+H]⁺ 309.9537, found 309.9533.
30
31
32

33 **Diethyl 2-phenylpyrrolo[1,2-b]isothiazole-4,5-dicarboxylate 1,1-dioxide (3h):** Colorless solid
34
35 (164 mg, 81%); mp.231-233 °C; IR (KBr, cm⁻¹): 3272, 2975, 1710, 1667, 1255, 1066, 752; ¹H
36
37 NMR (CDCl₃): δ 7.75-7.73 (m, 2H), 7.70 (d, *J* = 0.3 Hz, 1H), 7.62 (s, 1H), 7.53-7.52 (m, 3H),
38
39 4.44 (q, *J* = 7.1 Hz, 2H), 4.44 (q, *J* = 7.1 Hz, 2H), 1.44 (t, *J* = 7.1 Hz, 3H), 1.40 (t, *J* = 7.1 Hz,
40
41 3H); ¹³C NMR (CDCl₃): δ 161.7, 161.4, 130.6, 130.0, 129.3, 127.7, 126.6, 124.8, 119.5, 114.4,
42
43 61.6, 61.2, 14.3, 14.1; HRMS (ESI) *m/z* calcd for C₁₈H₁₈NO₆S [M+H]⁺ 376.0855, found
44
45 376.0857.
46
47
48
49

50 **Ethyl 4-methyl-2-phenylpyrrolo[1,2-b]isothiazole-5-carboxylate 1,1-dioxide (3i):** Colorless
51
52 solid (125 mg, 79%); mp.290-292 °C; IR (KBr, cm⁻¹): 3421, 1711, 1637, 1355, 1150, 1070, 763,
53
54 568; ¹H NMR (CDCl₃): δ 7.78 (s, 1H), 7.70-7.68 (dd, *J* = 1.7, 8.1 Hz, 2H), 7.50-7.45 (m, 3H),
55
56 7.30 (s, 1H), 4.35 (q, *J* = 7.1 Hz, 2H), 2.38 (s, 3H), 1.39 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (CDCl₃): δ
57
58
59
60

1
2
3
4
5
6 163.1, 130.2, 130.1, 129.4, 128.9, 127.7, 127.6, 125.7, 124.6, 123.3, 122.6, 120.5, 120.2, 60.3,
7
8 14.2, 11.4; HRMS (ESI) m/z calcd for $C_{16}H_{16}NO_4S$ $[M+H]^+$ 318.0800, found 318.0797.

9
10
11 **Methyl 4-methyl-2-phenylpyrrolo[1,2-b]isothiazole-5-carboxylate 1,1-dioxide (3j):** Colorless
12 solid (130 mg, 86%); mp.143-145 °C; IR (KBr, cm^{-1}): 3444, 2924, 1634, 1332, 1161, 749, 562;
13
14
15
16 1H NMR ($CDCl_3$): δ 7.77 (s, 1H), 7.70 (dd, $J = 1.6, 7.8$ Hz, 2H), 7.51-4.45 (m, 3H), 7.30 (s, 1H),
17
18 3.86 (s, 3H), 2.38 (s, 3H); ^{13}C NMR ($CDCl_3$): δ 163.8, 138.9, 130.1, 129.4, 126.8, 126.6, 125.7,
19
20 123.3, 122.5, 121.5, 117.2, 51.5, 10.2; HRMS (ESI) m/z calcd for $C_{15}H_{14}NO_4S$ $[M+H]^+$
21
22 304.0644, found 304.0648.

23
24
25
26 **5,6-Dibromo-2-phenylpyrrolo[1,2-b]isothiazole 1,1-dioxide (3k):** Colorless solid (125 mg,
27
28 65%); mp.193-196 °C; IR (KBr, cm^{-1}): 3432, 2924, 2075, 1638, 1247, 749; 1H NMR ($CDCl_3$): δ
29
30 7.68-7.66 (m, 2H), 7.50-7.48 (m, 3H), 7.11 (s, 1H), 6.38 (s, 1H); ^{13}C NMR ($CDCl_3$): δ 140.3,
31
32 130.5, 129.8, 129.5, 126.3, 126.0, 116.5, 112.1, 107.2, 103.3; HRMS (ESI) m/z calcd for
33
34 $C_{12}H_8Br_2NO_2S$ $[M+H]^+$ 387.8642, found 387.8649.

35
36
37
38 **Ethyl 2-(4-bromophenyl)pyrrolo[1,2-b]isothiazole-6-carboxylate 1,1-dioxide (3l):** Colorless
39
40 solid (72 mg, 38%); mp.189-191 °C; IR (KBr, cm^{-1}): 3434, 2923, 1638, 1459, 1329, 749; 1H
41
42 NMR ($CDCl_3$): δ 7.65-7.60 (m, 4H), 7.21 (s, 1H), 7.04 (d, $J = 3.7$ Hz, 1H), 6.36 (d, $J = 3.7$ Hz,
43
44 1H), 4.48 (q, $J = 7.1$ Hz, 2H), 1.46 (t, $J = 7.0$ Hz, 3H); ^{13}C NMR ($CDCl_3$): δ 158.6, 141.5, 132.7,
45
46 127.5, 127.2, 125.7, 125.0, 122.6, 116.8, 109.0, 107.5, 61.8, 14.1; HRMS (ESI) m/z calcd for
47
48 $C_{15}H_{13}BrNO_4S$ $[M+H]^+$ 381.9749, found 381.9744.

49
50
51
52
53 **Ethyl 2-(4-chlorophenyl)pyrrolo[1,2-b]isothiazole-6-carboxylate 1,1-dioxide (3m):** Yellow
54
55 solid (103 mg, 61%); mp.174-176 °C; IR (KBr, cm^{-1}): 3439, 2925, 1656, 1459, 743; 1H NMR
56
57 ($CDCl_3$): δ 7.69 (d, $J = 8.5$ Hz, 2H), 7.49 (d, $J = 8.4$ Hz, 2H), 7.19 (s, 1H), 7.04 (d, $J = 3.6$ Hz,
58
59

1
2
3
4
5
6 1H), 6.35 (d, $J = 3.6$ Hz, 1H), 4.48 (q, $J = 7.0$ Hz, 2H), 1.46 (d, $J = 7.1$ Hz, 3H); ^{13}C NMR
7
8 (CDCl₃): δ 158.5, 141.5, 136.7, 132.6, 129.7, 127.4, 127.1, 125.2, 122.6, 116.8, 108.9, 61.8,
9
10 14.1; HRMS (ESI) m/z calcd for C₁₅H₁₃ClNO₄S [M+H]⁺ 338.0254, found 338.0250.

11
12
13
14 **Ethyl 2-(*p*-tolyl)pyrrolo[1,2-*b*]isothiazole-6-carboxylate 1,1-dioxide (3n):** Off-white solid
15
16 (106 mg, 67%); mp.143-144 °C; IR (KBr, cm⁻¹): 3429, 2918, 1638, 1329, 566; ^1H NMR
17
18 (CDCl₃): δ 7.65 (d, $J = 8.2$ Hz, 2H), 7.31 (d, $J = 8.1$ Hz, 2H), 7.14 (s, 1H), 7.03 (d, $J = 3.6$ Hz,
19
20 1H), 6.30 (d, $J = 3.6$ Hz, 1H), 4.47 (q, $J = 7.1$ Hz, 2H), 2.42 (s, 3H), 1.46 (q, $J = 7.2$ Hz, 3H); ^{13}C
21
22 NMR (CDCl₃): δ 158.7, 142.8, 141.1, 133.1, 130.1, 126.7, 126.1, 123.9, 122.5, 115.3, 108.2,
23
24 61.7, 22.6, 14.1; HRMS (ESI) m/z calcd for C₁₆H₁₆NO₄S [M+H]⁺ 318.0800, found 318.0804.

25
26
27
28 **6-Phenylimidazo[1,2-*b*]isothiazole 5,5-dioxide (3o):** Yellow solid (90 mg, 78%); mp.140-141
29
30 °C; IR (KBr, cm⁻¹): 3428, 3032, 1348, 1173, 757, 558; ^1H NMR (CDCl₃): δ 7.77-7.74 (m, 2H),
31
32 7.55-7.53 (m, 3H), 7.40 (d, $J = 1.0$ Hz, 1H), 7.36 (s, 1H), 7.30 (d, $J = 1.5$ Hz, 1H); ^{13}C NMR
33
34 (CDCl₃): δ 148.0, 144.3, 136.0, 131.4, 129.6, 126.5, 125.9, 116.6, 115.2; HRMS (ESI) m/z calcd
35
36 for C₁₁H₉N₂O₂S [M+H]⁺ 233.0385, found 233.0383.

37
38
39
40
41 **1-(Benzylsulfonyl)-1*H*-imidazole-4-carbaldehyde (3p):** Colorless solid (88 mg, 71%); mp.167-
42
43 168 °C; IR (KBr, cm⁻¹): 3284, 3131, 1680, 1423, 1204, 763, 526; ^1H NMR (CDCl₃): δ 9.87 (s,
44
45 1H), 7.63 (d, $J = 1.1$ Hz, 1H), 7.52 (s, $J = 1.0$ Hz, 1H), 7.45 (t, $J = 7.4$ Hz, 1H), 7.38 (t, $J = 7.2$
46
47 Hz, 2H), 7.10 (d, $J = 7.3$ Hz, 2H), 4.62 (s, 2H); ^{13}C NMR (DMSO-D₆): δ 181.8, 138.6, 135.6,
48
49 132.8, 130.7, 128.9, 127.9, 126.6, 57.9; HRMS (ESI) m/z calcd for C₁₁H₁₁N₂O₃S [M+H]⁺
50
51 251.0490, found 251.0494.

52
53
54
55 **2-Phenylisothiazolo[2,3-*a*]indole 1,1-dioxide (3q):** Yellow solid (164 mg, 67%); mp.152-154
56
57 °C; IR (KBr, cm⁻¹): 2925, 2854, 1731, 1458, 1273, 758; ^1H NMR (CDCl₃): δ 7.81 (dd, $J = 1.6,$
58
59
60

1
2
3
4
5
6 7.8 Hz, 2H), 7.73 (d, $J = 8.0$ Hz, 1H), 7.63 (d, $J = 7.9$ Hz, 1H), 7.53-7.48 (m, 3H), 7.44-7.37 (m,
7
8 1H), 7.37 (s, 1H), 7.28-7.24 (m, 1H), 6.69 (s, 1H); ^{13}C NMR (CDCl_3): δ 143.5, 134.0, 132.8,
9
10 132.7, 130.5, 129.4, 126.9, 126.7, 126.1, 123.4, 122.9, 118.0, 111.5, 105.4; HRMS (ESI) m/z
11
12 calcd for $\text{C}_{16}\text{H}_{12}\text{NO}_2\text{S}$ $[\text{M}+\text{H}]^+$ 282.0589, found 282.0586.

13
14
15
16 **2-Phenyl-3H-pyrrolizin-3-one (3r):** Reddish solid (83 mg, 86%); mp.110-111 °C; IR (KBr, cm^{-1})
17
18 1): 3443, 1728, 1377, 1240, 779; ^1H NMR (CDCl_3): δ 7.80-7.77 (m, 2H), 7.43-7.39 (m, 2H),
19
20 7.36-7.32 (m, 1H), 7.23 (s, 1H), 6.98-6.97 (m 1H), 6.07-6.05 (m, 2H); ^{13}C NMR (CDCl_3): δ
21
22 165.0, 135.9, 133.1, 131.2, 129.8, 128.6, 128.4, 126.3, 118.8, 115.8, 111.5;HRMS (ESI) m/z
23
24 calcd for $\text{C}_{13}\text{H}_{10}\text{NO}$ $[\text{M}+\text{H}]^+$ 196.0762, found 196.0754.

25
26
27
28 **1-(((1R)-7,7-Dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl)methyl)sulfonyl)-1H-pyrrole-2-**
29
30 **carbaldehyde (3t):** Colorless solid (54 mg, 35%); mp.93-94 °C; IR (KBr, cm^{-1}): 3148, 2924,
31
32 2857, 1713, 1568, 1386, 1089, 757, 675; ^1H NMR (CDCl_3): δ 9.73 (d, $J = 0.7$ Hz, 1H), 7.62-7.61
33
34 (m, 1H), 7.24 (dd, $J = 1.7, 3.7$ Hz, 1H), 6.43 (t, $J = 3.5$ Hz, 1H), 4.11 (d, $J = 14.7$ Hz, 1H), 3.98
35
36 (d, $J = 14.6$ Hz, 1H), 2.55-2.38 (m, 2H), 2.18-2.06 (m, 2H), 1.99 (d, $J = 18.5$ Hz, 1H), 1.83-1.76
37
38 (m, 1H), 1.52-1.48 (m, 1H), 1.21 (s, 3H), 0.96 (s, 3H); ^{13}C NMR (CDCl_3): δ 214.0, 178.2, 133.0,
39
40 130.8, 129.1, 111.3, 58.9, 52.5, 48.3, 42.6, 42.5, 27.0, 25.2, 19.8, 19.6; HRMS (ESI) m/z calcd
41
42 for $\text{C}_{15}\text{H}_{20}\text{NO}_4\text{S}$ $[\text{M}+\text{H}]^+$ 310.1113, found 310.1110.

43
44
45
46
47 **1-(Ethylsulfonyl)-1H-pyrrole-2-carbaldehyde (3u):** Viscous oil (89 mg, 96%); IR (DCM, cm^{-1})
48
49 1): 3127, 2926, 1726,1364, 1167, 908, 611; ^1H NMR (CDCl_3): δ 9.74 (s, 1H), 7.59-7.58 (m, 1H),
50
51 7.26 (dd, $J = 1.7, 3.4$ Hz, 1H), 6.45 (t, $J = 3.4$ Hz, 1H), 3.86 (q, $J = 7.4$ Hz, 2H), 1.38 (t, $J = 7.4$
52
53 Hz, 3H); ^{13}C NMR (CDCl_3): δ 178.4, 133.2, 131.2, 128.5, 111.6, 49.6, 7.9; HRMS (ESI) m/z
54
55 calcd for $\text{C}_7\text{H}_{10}\text{NO}_3\text{S}$ $[\text{M}+\text{H}]^+$ 188.0381, found 188.0388.
56
57
58
59
60

1
2
3
4
5
6 **2-(Trifluoromethyl)pyrrolo[1,2-b]isothiazole 1,1-dioxide (3v):** Semi-solid (10 mg, 9%); IR
7
8 (DCM, cm^{-1}): 2928, 1645, 1030, 774, 630; ^1H NMR (CDCl_3): δ 7.56 (s, 1H), 7.27 (d, $J = 2.9$ Hz,
9 1H), 6.62 (d, $J = 3.4$ Hz, 1H), 6.50 (t, $J = 3.2$ Hz, 1H); ^{13}C NMR (CDCl_3): δ 128.9, 128.9, 128.5,
10 125.5, 121.0, 117.9, 114.5; HRMS (ESI) m/z calcd for $\text{C}_7\text{H}_3\text{F}_3\text{NO}_2\text{S}$ $[\text{M}+\text{H}]^+$ 223.9993, found
11 223.9989.
12
13
14
15
16

17
18 **Methyl 3-((3-methoxy-3-oxopropyl)thio)-2-phenyl-2,3-dihydropyrrolo[1,2-b]isothiazole-6-**
19 **carboxylate 1,1-dioxide (4a):** Yellow Semi-solid (52 mg, 64%); IR (DCM, cm^{-1}): 2953, 2852,
20 1723, 1482, 1366, 1166, 753, 571, 529; ^1H NMR (CDCl_3): δ 7.58-7.50 (m, 5H), 7.14 (d, $J = 3.6$
21 Hz, 1H), 6.37 (d, $J = 3.6$ Hz, 1H), 5.10 (d, $J = 9.4$ Hz, 1H), 4.79 (d, $J = 9.4$ Hz, 1H), 3.92 (s, 3H),
22 3.67 (s, 3H), 2.69-2.66 (m, 2H), 2.48-2.44 (m, 2H); ^{13}C NMR (CDCl_3): δ 171.6, 159.1, 135.9,
23 130.6, 130.1, 129.4, 127.3, 123.2, 121.8, 106.9, 52.1, 52.0, 44.0, 34.2, 25.9; HRMS (ESI) m/z
24 calcd for $\text{C}_{18}\text{H}_{20}\text{NO}_6\text{S}_2$ $[\text{M}+\text{H}]^+$ 410.0732, found 410.0734.
25
26
27
28
29
30
31
32
33
34

35 **Methyl 3-((3-methoxy-3-oxopropyl)thio)-2-phenyl-2,3-dihydropyrrolo[1,2-b]isothiazole-6-**
36 **carboxylate 1,1-dioxide (4b):** Yellow Semi-solid (22 mg, 28%); IR (DCM, cm^{-1}): 2926, 2844,
37 1721, 1478, 1369, 1170, 775, 580; ^1H NMR (CDCl_3): δ 7.45-7.38 (m, 3H), 7.24 (d, $J = 7.3$ Hz,
38 2H), 7.13 (d, $J = 3.7$ Hz, 1H), 6.36 (d, $J = 3.6$ Hz, 1H), 5.30 (d, $J = 6.8$ Hz, 1H), 5.09 (d, $J = 6.8$
39 Hz, 1H), 3.91 (s, 3H), 3.69 (s, 3H), 2.79-2.64 (m, 2H), 2.56 (t, $J = 6.9$ Hz, 2H); ^{13}C NMR
40 (DCM): δ 171.8, 159.1, 137.8, 130.2, 130.1, 128.9, 128.8, 123.2, 122.5, 106.7, 52.2, 52.0, 43.4,
41 34.5, 27.8; HRMS (ESI) m/z calcd for $\text{C}_{18}\text{H}_{20}\text{NO}_6\text{S}_2$ $[\text{M}+\text{H}]^+$ 410.0732, found 410.0734.
42
43
44
45
46
47
48
49
50
51

52 **Methyl 2-phenyl-3-(propylamino)-2,3-dihydropyrrolo[1,2-b]isothiazole-6-carboxylate 1,1-**
53 **dioxide (4c):** Viscous oil (66 mg, 95%); IR (DCM, cm^{-1}): 3332, 2927, 1706, 1497, 1497, 1353,
54 1167, 751, 598; ^1H NMR (CDCl_3): δ 7.48 (s, 5H), 7.14 (d, $J = 3.7$ Hz, 1H), 6.33 (q, $J = 0.8, 3.6$
55
56
57
58
59
60

1
2
3
4
5
6 Hz, 1H), 4.99 (d, $J = 7.3$ Hz, 1H), 4.85 (dd, $J = 0.8, 7.3$ Hz, 1H), 3.91 (s, 3H), 2.64-2.53 (m, 2H),
7
8 1.49-1.40 (m, 2H), 0.89 (t, $J = 7.3$ Hz, 3H); ^{13}C NMR (CDCl_3): δ 159.2, 138.7, 130.1, 129.7,
9
10 129.3, 128.7, 123.2, 121.2, 105.7, 58.1, 52.0, 47.9, 23.3, 11.5; HRMS (ESI) m/z calcd for
11
12 $\text{C}_{17}\text{H}_{21}\text{N}_2\text{O}_4\text{S}$ $[\text{M}+\text{H}]^+$ 349.1222, found 349.1218.

13
14
15
16 **Methyl 3-morpholino-2-phenyl-2,3-dihydropyrrolo[1,2-b]isothiazole-6-carboxylate 1,1-**
17
18 **dioxide (4d):** Colorless solid (69 mg, 93%); mp.178-180 °C; IR (KBr, cm^{-1}):3390, 2928, 2852,
19
20 1705, 1493, 1353, 1154, 1083, 856, 750, 574; ^1H NMR (CDCl_3): δ 7.50-7.47 (m, 5H), 7.15 (d, J
21
22 = 3.6 Hz, 1H), 6.29 (d, $J = 3.6$ Hz, 1H), 5.18 (d, $J = 7.2$ Hz, 1H), 4.90 (d, $J = 7.2$ Hz, 1H), 3.89
23
24 (s, 3H), 3.67-3.61 (m, 4H), 2.59-2.53 (m, 4H); ^{13}C NMR (CDCl_3): δ 159.1, 136.0, 130.1, 129.7,
25
26 129.7, 129.4, 123.5, 121.4, 106.5, 70.3, 66.9, 65.5, 52.1, 49.2; HRMS (ESI) m/z calcd for
27
28 $\text{C}_{18}\text{H}_{21}\text{N}_2\text{O}_5\text{S}$ $[\text{M}+\text{H}]^+$ 377.1171, found 377.1165.

29
30
31
32
33 **Methyl 2-phenyl-2,3-dihydropyrrolo[1,2-b]isothiazole-6-carboxylate 1,1-dioxide (4e):**
34
35 Colorless solid (54 mg, 93%); mp.148-149 °C; IR (KBr, cm^{-1}): 2953, 1712, 1483, 1360, 1170,
36
37 754, 585; ^1H NMR (CDCl_3): δ 7.52-7.48 (m, 5H), 7.11 (d, $J = 3.6$ Hz, 1H), 6.16 (d, $J = 3.6$ Hz,
38
39 1H), 5.21 (t, $J = 8.8$ Hz, 1H), 3.91 (s, 3H), 3.76-3.61 (m, 2H); ^{13}C NMR (CDCl_3): δ 159.2, 134.8,
40
41 130.2, 129.3, 129.3, 129.0, 123.2, 121.1, 105.5, 71.2, 52.0, 28.0; HRMS (ESI) m/z calcd for
42
43 $\text{C}_{14}\text{H}_{14}\text{NO}_4\text{S}$ $[\text{M}+\text{H}]^+$ 292.0644, found 292.0645.

44
45
46
47
48 **Methyl 2-benzyl-3a-phenyl-2,3,3a,8b-tetrahydro-1H-dipyrrolo[1,2-b:3',4'-d]isothiazole-6-**
49
50 **carboxylate 4,4-dioxide (4f):** Yellow solid (68 mg, 81%); mp.126-127 °C; IR (KBr, cm^{-1}):
51
52 2924, 2853, 1713, 1441, 1157, 954, 753; ^1H NMR (CDCl_3): δ 7.42-7.41 (m, 2H), 7.34-7.29 (m,
53
54 8H), 7.20 (d, $J = 3.6$ Hz, 1H), 6.12 (d, $J = 3.5$ Hz, 1H), 4.43-4.38 (m, 2H), 3.89 (s, 3H), 3.81 (d, J
55
56 = 13.5 Hz, 1H), 3.70 (d, $J = 13.5$ Hz, 1H), 3.24 (d, $J = 8.8$ Hz, 1H), 2.99 (d, $J = 10.8$ Hz, 1H),
57
58
59
60

1
2
3
4
5
6 2.82 (t, $J = 7.0$ Hz, 1H); ^{13}C NMR (CDCl_3): δ 159.2, 138.5, 137.2, 134.8, 129.4, 129.0, 128.4,
7
8 128.3, 127.9, 127.3, 124.8, 120.6, 104.1, 83.2, 62.1, 60.8, 58.3, 51.9, 45.8; HRMS (ESI) m/z
9
10 calcd for $\text{C}_{23}\text{H}_{23}\text{N}_2\text{O}_4\text{S}$ $[\text{M}+\text{H}]^+$ 423.1379, found 423.1373.
11
12

13
14 **Ethyl 2-benzyl-3a-phenyl-2,3,3a,8b-tetrahydro-1H-dipyrrolo[1,2-b:3',4'-d]isothiazole-6-**
15 **carboxylate 4,4-dioxide (4g):** Colorless solid (77 mg, 89%); mp.111-112 °C; IR (KBr, cm^{-1}):
16 2924, 2853, 1713, 1485, 1175, 698, 585; ^1H NMR (CDCl_3): δ 7.43-7.27 (m, 10H), 7.21 (d, $J =$
17 3.6 Hz, 1H), 6.11 (d, $J = 3.6$ Hz, 1H), 4.42-4.31 (m, 4H), 3.79 (q, $J = 13.5$ Hz, 2H), 3.22 (d, $J =$
18 8.8 Hz, 1H), 3.01 (d, $J = 10.7$ Hz, 1H), 2.81 (dd, $J = 6.8, 8.6$ Hz, 1H), 1.39 (t, $J = 7.1$ Hz, 3H);
19
20 ^{13}C NMR (CDCl_3): δ 158.7, 137.2, 134.7, 129.5, 129.0, 128.5, 127.8, 124.6, 121.1, 104.2, 83.2,
21 68.5, 61.1, 60.6, 58.4, 45.7, 14.1; HRMS (ESI) m/z calcd for $\text{C}_{24}\text{H}_{25}\text{N}_2\text{O}_4\text{S}$ $[\text{M}+\text{H}]^+$ 437.1535,
22
23 found 437.1538.
24
25
26
27
28
29
30
31
32

33 **(Z)-Ethyl 1-phenyl-2-(1H-pyrrol-2-yl)ethenesulfonate (5a):** Off-white solid (22 mg, 41%);
34 mp.85-87 °C; IR (KBr, cm^{-1}): 3351, 3107, 2339, 1655, 1187, 825, 623; ^1H NMR (CDCl_3): δ 7.63
35 (s, 1H), 7.57-7.50 (m, 5H), 6.71 (d, $J = 0.9$ Hz, 1H), 6.45 (s, 1H), 6.20-6.18 (m, 1H), 4.20 (q, $J =$
36 7.1 Hz, 2H), 1.35 (t, $J = 7.1$ Hz, 3H); ^{13}C NMR (CDCl_3): δ 131.5, 130.7, 130.0, 130.0, 129.7,
37
38 126.6, 125.8, 123.7, 118.7, 110.4, 66.8, 14.8; HRMS (ESI) m/z calcd for $\text{C}_{14}\text{H}_{16}\text{NO}_3\text{S}$ $[\text{M}+\text{H}]^+$
39
40 278.0851, found 278.0854.
41
42
43
44
45
46
47

48 **(E)-2-styryl-1H-pyrrole (5b):** Colorless solid (13 mg, 34%); mp.128-130 °C; IR (KBr, cm^{-1}):
49 3297, 2971, 1639, 1385, 1102; ^1H NMR (CDCl_3): δ 8.38 (bs, 1H), 7.47 (d, $J = 7.5$ Hz, 2H), 7.38
50 (t, $J = 7.4$ Hz, 2H), 7.27 (t, $J = 7.2$ Hz, 1H), 7.03 (d, $J = 16.4$ Hz, 1H), 6.84 (d, $J = 1.1$ Hz, 1H),
51
52 6.71 (d, $J = 16.4$ Hz, 1H), 6.40 (s, 1H), 6.30-6.28 (m, 1H); ^{13}C NMR (CDCl_3): δ 137.5, 130.8,
53
54
55
56
57
58
59
60

1
2
3
4
5
6 128.7, 126.9, 125.8, 123.3, 119.2, 119.0, 110.0, 109.2; HRMS (ESI) m/z calcd for C₁₂H₁₂NO
7
8 [M+H]⁺ 170.0970, found 170.0972.
9

10
11 **(Z)-Ethyl 2-(4-cyano-1H-pyrrol-2-yl)-1-phenylethanesulfonate (5c):** Off-white solid (53 mg,
12 88%); mp.161-162 °C; IR (KBr, cm⁻¹): 3258, 2923, 2229, 1632, 1348, 1167, 908, 611; ¹H NMR
13 (CDCl₃): δ 8.19 (bs, 1H), 7.60-7.58 (m, 4H), 7.48-7.46 (m, 2H), 7.15 (s, 1H), 6.50 (s, 1H), 4.20
14 (q, *J* = 7.0 Hz, 2H), 1.35 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (CDCl₃): δ 132.1, 130.6, 130.5, 130.2,
15 130.0, 129.0, 128.8, 127.8, 126.8, 126.7, 118.9, 115.2, 95.4, 67.6, 14.8; HRMS (ESI) m/z calcd
16 for C₁₅H₁₅N₂O₃S [M+H]⁺ 303.0803, found 303.0807.
17
18
19
20
21
22
23
24
25

26 **(Z)-Ethyl 2-(5-bromo-1H-pyrrol-2-yl)-1-phenylethanesulfonate (5d):** Yellowish solid (54 mg,
27 76%); mp.136-138 °C; IR (KBr, cm⁻¹): 3247, 2165, 1478, 1298, 911, 586; ¹H NMR (CDCl₃): δ
28 7.59-7.58 (m, 3H), 7.51-7.49 (m, 3H), 7.45 (bs, 1H), 6.34 (t, *J* = 3.6 Hz, 1H), 6.14 (dd, *J* = 2.4,
29 3.7 Hz, 1H), 4.20 (q, *J* = 7.12 Hz, 2H), 1.41 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (CDCl₃): δ 131.1,
30 130.9, 130.4, 130.2, 129.8, 128.7, 127.1, 119.7, 112.6, 61.6, 14.1; HRMS (ESI) m/z calcd for
31 C₁₄H₁₅BrNO₃S [M+H]⁺ 355.9956, found 355.9961.
32
33
34
35
36
37
38
39
40

41 **Methyl (E)-5-styryl-1H-pyrrole-2-carboxylate (5e):** Colorless solid (30 mg, 67%); mp.158-
42 160 °C; IR (KBr, cm⁻¹): 3382, 2956, 1685, 1489, 1159, 758, 611; ¹H NMR (CDCl₃): δ 9.35(bs,
43 1H), 7.49 (d, *J* = 7.4 Hz, 2H); 7.39 (t, *J* = 7.4 Hz, 2H); 7.30 (t, *J* = 7.3 Hz, 1H), 6.95-6.93 (m,
44 3H), 6.41 (t, *J* = 2.7 Hz, 1H), 3.89 (s, 3H); ¹³C NMR (CDCl₃): δ 161.5, 136.6, 135.3, 128.8,
45 128.1, 127.9, 126.3, 122.7, 117.6, 116.7, 110.1, 51.6; HRMS (ESI) m/z calcd for C₁₄H₁₄NO₂
46 [M+H]⁺ 228.1025, found 228.1019.
47
48
49
50
51
52
53
54

55 **Ethyl (E)-5-styryl-1H-pyrrole-2-carboxylate (5f):** Colorless solid (26 mg, 55%); mp.140-141
56 °C; IR (KBr, cm⁻¹): 3325, 2855, 1715, 1649, 1082, 727, 539; ¹H NMR (CDCl₃): δ 9.30 (bs, 1H),
57
58
59
60

1
2
3
4
5
6 7.49 (d, $J = 7.3$ Hz, 2H), 7.39 (t, $J = 7.3$ Hz, 2H), 7.30 (t, $J = 8.8$ Hz, 1H), 6.95-6.92 (m, 3H),
7
8 6.41 (dd, $J = 2.7, 3.6$ Hz, 1H), 4.39 (q, $J = 7.1$ Hz, 2H), 1.41 (t, $J = 7.1$ Hz, 3H); ^{13}C NMR
9
10 (CDCl₃): δ 161.1, 136.6, 135.2, 128.7, 127.9, 127.8, 126.3, 123.1, 117.7, 116.5, 110.1, 60.5,
11
12 14.5; HRMS (ESI) m/z calcd for C₁₅H₁₆NO₂ [M+H]⁺ 242.1181, found 242.1175.

13
14
15
16 **2-(Phenylethynyl)-1H-pyrrole (5g)**: Colorless solid (24 mg, 73%); mp.93-94 °C; IR (KBr, cm⁻¹)
17
18 ¹): 3435, 2952, 2853, 1743, 1463, 755; ^1H NMR (CDCl₃): δ 8.43 (bs, 1H), 7.49-7.46 (m, 2H),
19
20 7.35-7.25 (m, 3H), 6.80 (d, $J = 1.0$ Hz, 1H), 6.54 (s, 1H), 6.24 (q, $J = 3.0$ Hz, 1H); ^{13}C NMR
21
22 (CDCl₃): δ 131.1, 128.3, 128.0, 123.2, 119.6, 114.9, 112.9, 109.4, 90.3, 81.8; HRMS (ESI) m/z
23
24 calcd for C₁₂H₁₀N [M+H]⁺ 168.0813, found 168.0818.

25
26
27
28 **Methyl 5-(phenylethynyl)-1H-pyrrole-2-carboxylate (5h)**: White solid (36 mg, 81%); mp.116-
29
30 117 °C; IR (KBr, cm⁻¹): 3317, 3304, 2284, 1672, 1491, 1226, 773; ^1H NMR (CDCl₃): δ 9.01 (bs,
31
32 1H), 7.33-7.30 (m, 2H), 7.26-7.18 (m, 3H), 6.85 (dd, $J = 2.7, 0.9$ Hz, 1H), 6.01 (t, $J = 3.1$ Hz,
33
34 1H), 3.84 (s, 3H); ^{13}C NMR (CDCl₃): δ 161.6, 140.8, 137.8, 128.5, 128.3, 126.3, 121.0, 115.9,
35
36 108.4, 51.3; HRMS (ESI) m/z calcd for C₁₄H₁₂NO₂ [M+H]⁺ 226.0868, found 226.0865.

37
38
39
40
41 **5-(Phenylethynyl)-1H-pyrrole-3-carbonitrile (5i)**: Buff solid (25 mg, 66%); mp.93-94 °C; IR
42
43 (KBr, cm⁻¹): 3310, 3307, 2961, 2249, 2210, 1767, 1223, 798; ^1H NMR (CDCl₃): δ 8.81 (bs, 1H),
44
45 7.52-7.50 (m, 2H), 7.39-7.38 (m, 3H), 7.30-7.29 (m, 1H), 6.75 (d, $J = 1.6$ Hz, 1H); ^{13}C NMR
46
47 (CDCl₃): δ 131.4, 128.9, 128.5, 126.2, 121.9, 116.8, 115.7, 94.5, 91.6; HRMS (ESI) m/z calcd
48
49 for C₁₃H₉N₂ [M+H]⁺ 193.0766, found 193.0761.

50
51
52
53 **6-Bromo-2-phenylpyrrolo[1,2-b]isothiazole 1,1-dioxide (6)**: Colorless solid (56 mg, 92%);
54
55 mp.123-125 °C; IR (KBr, cm⁻¹): 3430, 2960, 1723, 1286, 744; ^1H NMR (CDCl₃): δ 7.68 (d, $J =$
56
57 7.5 Hz, 2H), 7.51-7.45 (m, 3H), 7.12 (s, 1H), 6.34 (d, $J = 3.4$ Hz, 1H), 6.27 (d, $J = 3.5$ Hz, 1H);
58
59
60

¹³C NMR (CDCl₃): δ 139.9, 130.5, 130.1, 129.4, 126.8, 125.8, 118.7, 117.3, 110.5, 102.1;

HRMS (ESI) m/z calcd for C₁₂H₉BrNO₂S [M+H]⁺ 309.9537, found 309.9540.

ASSOCIATED CONTENT

Supporting Information

Copies of ¹H and ¹³C NMR spectra of new compounds. This material is available free of charge via the Internet at <http://pubs.acs.org>.

AUTHOR INFORMATION

Corresponding Author

*E-mail: jlaha@niper.ac.in.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENT

The financial support from the SERB, New Delhi is greatly appreciated. SS and SK thank to the NIPER S.A.S. Nagar and DBT, New Delhi for the award of Senior Research Fellowships, respectively.

REFERENCES

- (1) (a) Li, X.; Liu, D. R. *Angew. Chem. Int. Ed.* **2004**, *43*, 4848-4870. (b) Van Bommel, K. J. C.; Friggeri, A.; Shinkai, S. *Angew. Chem. Int. Ed.* **2003**, *42*, 980-999.

- 1
2
3
4
5
6 (2) Ref for small organic molecule template: (a) Yao, H.; Gao, M.; Yu, S. *Nanoscale* **2010**, *2*,
7 322-334. (b) Joseph, C. G.; Wilson, K. R.; Wood, M. S.; Sorenson, N. B.; Phan, D. V.; Xiang,
8 Z.; Witek, R. M.; Haskell-Luevano, C. *J. Med. Chem.* **2008**, *51*, 1423-1431.
9
10
11
12
13
14 (3) (a) Du, M.; Bu, Y.; Zhou, Y.; Zhao, Y.; Wang, S.; Xu, H. *RSC Adv.* **2017**, *7*, 12711-
15 12718. (b) Kanan, M. W.; Rozenman, M. M.; Sakurai, K.; Synder, T. M.; Liu, D. R. *Nature*
16 **2004**, *431*, 545-549. (c) Greenwell, D. R.; Ibnouzaki, A. F.; Warriner, S. L. *Angew. Chem. Int.*
17 *Ed.* **2002**, *41*, 1215-1218. (d) Gartner, Z. J.; Liu, D. R. *J. Am. Chem. Soc.* **2001**, *123*, 6961-6963.
18
19
20
21
22
23
24 (4) (a) Gennari, C.; Nestler, H. P.; Salom, B.; Still, W. C. *Angew. Chem. Int. Ed.* **1995**, *34*, 1765-
25 1768. (b) Gennari, C.; Salom, B.; Potenza, D.; Williams, A. *Angew. Chem. Int. Ed.* **1994**, *33*,
26 2067-2069.
27
28
29
30
31
32 (5) (a) Azevedo, C. M. G.; Watterson, K. R.; Wargent, Ed T.; Hansen, S. V. F.; Hudson, B. D.;
33 Kępczyńska, M. A.; Dunlop, J.; Shimpukade, B.; Christiansen, E.; Milligan, G.; Stocker, C. J.;
34 Ulven, T. *J. Med. Chem.* **2016**, *59*, 8868-8878. (b) Kiefer, L.; Gorojankina, T.; Dauban, P.;
35 Faure, H.; Ruat, M.; Dodd, R. H. *Bioorg. Med. Chem. Lett.* **2010**, *20*, 7483-7487. (c) Lapierre, J.;
36 Rotstein, D. M.; Sjogren, E. B. PCT Int. Appl. WO0228810, **2002**. (d) Roush, W. R.; Cheng, J.;
37 Knapp-Reed, B.; Alvarez-Hernandez, A.; McKerrow, J. H.; Hansell, E.; Engel, J. C. *Bioorg.*
38 *Med. Chem. Lett.* **2001**, *11*, 2759-2762. (e) Chapman, J. M.; Cocolas, Jr. G. H.; Hall, I. H. *J.*
39 *Med. Chem.* **1983**, *26*, 243-246.
40
41
42
43
44
45
46
47
48
49
50
51 (6) Ref for biomaterials: (a) Swinnen, D.; Jorand-Lebrun, C.; Grippi-Vallotton, T.; Gerber, P.;
52 Gonzalez, J.; Shaw, J.; Jeyaprakashnarayanan, S. PCT Int. Appl. 2010100144, **2010**. (b) Shan,
53 W.; Balog, J. A.; Nation, A. J.; Gavai, A. V.; Han, W.; Salvati, M. E. PCT Int. Appl.
54 2008030902, **2008**. (c) Na, K.; Bae, Y. H. *Pharm. Res.* **2002**, *19*, 681-688.
55
56
57
58
59
60

- 1
2
3
4
5
6 (7) (a) Lopez-Jaramillo, F. J.; Hernandez-Mateo, F.; Santoyo-Gonzalez, F. *Vinyl sulfone: a*
7 *multi-purpose function in proteomics in Integrative proteomics*, InTech, **2012**, p. 301. (b)
8
9 Meadows, D. C.; Gervay-Hague, J. *Med. Res. Rev.* **2006**, *26*, 793-814.
10
11
12
13 (8) (a) Reddick, J. J.; Cheng, J.; Roush, W. R. *Org. Lett.* **2003**, *5*, 1967-1970. (b) Roush, W. R.;
14
15 Gwaltney II, S. L.; Cheng, J.; Scheidt, K. A.; McKerrow, J. H.; Hansell, E. *J. Am. Chem. Soc.*
16
17 **1998**, *120*, 10994-10995.
18
19
20
21 (9) (a) Lima, L. M.; Barreiro, E. J. *Curr. Med. Chem.* **2005**, *12*, 23-49. (b) Thornber, C. W.
22
23 *Chem. Soc. Rev.* **1979**, *8*, 563-580.
24
25
26
27 (10) (a) Kalgutkar, A.; Jones, R.; Sawant, A. In *Metabolism Pharmacokinetics and Toxicity of*
28 *Functional Groups*; Smith, D. A., Ed.; RSC: Cambridge, UK, **2010**; RSC Drug Discovery Series
29
30 No. 1, Chapter 5. (b) Hansch, C.; Sammes, P. G.; Taylor, J. B. *Comprehensive Medicinal*
31
32 *Chemistry*; Pergamon Press: Oxford, UK, **1990**; Vol. 2, Chapter 7.1.
33
34
35
36
37 (11) For selected references, see: (a) Asad, N.; Samarakoon, T. B.; Zang, Q.; Loh, J. K.; Javed,
38
39 S.; Hanson, P. R. *Org. Lett.* **2013**, *16*, 82-85. (b) Ji, T.; Wang, Y.; Wang, M.; Niu, B.; Xie, P.;
40
41 Pittman Jr., C. U.; Zhou, A. *ACS Comb. Sci.* **2013**, *15*, 595-600. (c) Zhou, A.; Rayabarapu, D.;
42
43 Hanson, P. R. *Org. Lett.* **2009**, *11*, 531-534. (d) Zhao, M. M.; Qu, C.; Lynch, J. E. *J. Org. Chem.*
44
45 **2005**, *70*, 6944-6947. (e) Makara, G. M.; Ma, Y. *Tetrahedron Lett.* **2001**, *42*, 4123-4125.
46
47
48
49 (12) (a) Suh, E. H.; Liu, Y.; Connelly, S.; Genreux, J. C.; Wilson, I. A.; Kelly, J. W. *J. Am.*
50
51 *Chem. Soc.* **2013**, *135*, 17869-17880. (b) Lu, X.; Olsen, S. K.; Capili, A. D.; Cisar, J. S.; Lima,
52
53 C. D.; Tan, D. S. *J. Am. Chem. Soc.* **2010**, *132*, 1748-1749.
54
55
56
57
58
59
60

- 1
2
3
4
5
6 (13) (a) Schmidt, B.; Wolf, F.; Brunner, H. *Eur. J. Org. Chem.* **2016**, *2016*, 2972-2982. (b)
7
8 Reuter, D. C.; McIntosh, J. E.; Guinn, A. C.; Madera, A. M. *Synthesis*, **2003**, 2321-2324.
9
10
11 (14) Laha, J. K.; Dayal, N.; Jethava, K. P.; Prajapati, D. V. *Org. Lett.* **2015**, *17*, 1296-1299.
12
13
14
15 (15) Laha, J. K.; Jethava, K. P.; Dayal, N. *J. Org. Chem.* **2014**, *79*, 8010-8019.
16
17
18 (16) Laha, J. K.; Sharma, S.; Dayal, N. *Eur. J. Org. Chem.* **2015**, *2015*, 7885-7891.
19
20
21 (17) Singh, G.; Kumar, R.; Swett, J.; Zajc, B. *Org. Lett.* **2013**, *15*, 4086-4089.
22
23
24 (18) (a) Nájera, C.; Yus, V. *Tetrahedron* **1999**, *55*, 10547-10658. (b) Mandai, T.; Yanagi, T.;
25
26 Araki, K.; Morisaki, Y.; Kawada, M.; Otera, J. *J. Am. Chem. Soc.* **1984**, *106*, 3670-3672.
27
28
29 (19) Van Leusen, M.; Siderius, H.; Hoogenboom, B. E.; van Leusen, D. *Tetrahedron Lett.* **1972**,
30
31 *52*, 5337-5340.
32
33
34
35 (20) Chen, C. Y.; Bocian, D. F.; Lindsey, J. S. *J. Org. Chem.* **2014**, *79*, 1001-1016.
36
37
38 (21) Yanga, S.; Suna, B.; Ou, Z.; Menga, D.; Lua, G.; Fangb, Y.; Kadish, K. M. *J. Porphyrins*
39
40 *Phthalocyanines* **2013**, *17*, 1-13.
41
42
43 (22) Gilow, H. M.; Burton, D. E. *J. Org. Chem.* **1981**, *46*, 2221-2225.
44
45
46 (23) Sadeghzadeh, M.; Sheibani, S.; Ghandi, M.; Daha, F. J.; Amanlou, M.; Arjmand, M.;
47
48 Bozcheloie, A. H. *Eur. J. Med. Chem.* **2013**, *64*, 488-497.
49
50
51 (24) Pandey, G.; Laha, J. K.; Mohanakrishnan, A. *Tetrahedron Lett.* **1999**, *40*, 6065-6068.
52
53
54
55
56
57
58
59
60